Ladenburg analyst Matthew Kaplan reiterates his Buy rating and $5 price target on shares of Lipocine after the company announced interim results from the ongoing 16-week liver fat imaging study with LPCN 1144. He said he is encouraged by these preliminary, 8-week results, which show a rapid reduction in liver fat levels from baseline based on MRI assessment, and looks forward to the full study results later this year. Kaplan also noted that Lipocine is working to resolve the four issues detailed in the CRL received in May 2018 and he expects results from the “rate-limiting” AMB BP study in late Q1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.